ArticleEnvironmental research2025
Per- and polyfluoroalkyl substance concentrations during pregnancy and at birth and risk of childhood acute lymphoblastic leukemia.
Article in Environmental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted and non-targeted analyses of per-and polyfluoroalkyl substances in newborn dried blood spots and risk of childhood acute lymphoblastic leukemia.Journal of exposure science & environmental epidemiology · 2026Article
- The Unique Utility of Newborn Dried Blood Spots for Driving Discovery in Childhood Cancer Research.Clinical chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPer- and polyfluoroalkyl substances (PFAS) comprise a class of persistent environmental pollutants with potential carcinogenic effects, but their impact on childhood cancer remains underexplored. A child's exposure to PFAS can occur through various pathways postnatally, including contaminated food, water, and consumer products; and in utero, as PFAS can cross the placenta.
methodsTo investigate the association between early-life PFAS exposure and the risk of childhood acute lymphoblastic leukemia (ALL), we analyzed archived blood samples from children diagnosed with ALL and matched cancer-free controls. Using novel untargeted liquid chromatography-high resolution mass spectrometry (LC-HRMS), we measured PFAS levels in paired maternal pregnancy and child newborn blood samples.
resultsOur study identified an independent association between MeFOSAA levels at birth and increased ALL risk, particularly among children diagnosed at 2 years of age or younger. MeFOSAA measured in maternal second-trimester blood showed a weak association with ALL, although it was not statistically significant.
conclusionsThese results suggest that early-life exposure to MeFOSAA may play a critical role in the development of childhood ALL. Our findings corroborate previous reports linking MeFOSAA exposure during pregnancy to childhood ALL, highlighting its potential carcinogenicity during key developmental windows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.